Optimizing growth hormone replacement therapy by dose titration in hypopituitary adults.

Optimizing growth hormone replacement therapy by dose titration in hypopituitary adults.

Although growth hormone (GH) replacement therapy is increasingly utilized in the management of adult hypopituitary patients, optimum dosing schedules are poorly defined. The use of weight-based or surface area-based dosing may result in overtreatment, and individual variation in susceptibility on th...

Full description

Bibliographic Details
Main Authors:	Drake, WM, Coyte, D, Camacho-Hübner, C, Jivanji, N, Kaltsas, G, Wood, D, Trainer, P, Grossman, AB, Besser, G, Monson, J
Format:	Journal article
Language:	English
Published:	1998

Similar Items

Sustained reduction in circulating cholesterol in adult hypopituitary patients given low dose titrated growth hormone replacement therapy: a two year study.
by: Florakis, D, et al.
Published: (2000)

Comments on 'Sustained reduction in circulating cholesterol in adult hypopituitary patients given low dose titrated growth hormone replacement therapy: a two-year study' by Florakis et al (2000) - Reply
by: Monson, J, et al.
Published: (2001)

Hypothalamo-pituitary surveillance imaging in hypopituitary patients receiving long-term GH replacement therapy.
by: Frajese, G, et al.
Published: (2001)

Safety of GH replacement in hypopituitary patients with nonirradiated pituitary and peripituitary tumours.
by: Chung, T, et al.
Published: (2008)

Unmasking of central hypothyroidism following growth hormone replacement in adult hypopituitary patients.
by: Agha, A, et al.
Published: (2007)

Growth hormone replacement does not increase serum prostate-specific antigen in hypopituitary men over 50 years.
by: le Roux, C, et al.
Published: (2002)

Role of fasting plasma glucose, glycated haemoglobin and homeostatic model assessment in the detection of glucose intolerance in adult hypopituitary patients during growth hormone replacement therapy.
by: Colson, A, et al.
Published: (2008)

Tumour surveillance imaging in patients with extrapituitary tumours receiving growth hormone replacement.
by: Chung, T, et al.
Published: (2005)

Predictors of the outcome of surgical treatment in acromegaly and the value of the mean growth hormone day curve in assessing postoperative disease activity.
by: Kaltsas, G, et al.
Published: (2001)

Insulin-like growth factor-I and- II in combination inhibit the release of growth hormone-releasing hormone from the rat hypothalamus in vitro.
by: Korbonits, M, et al.
Published: (1996)

The effect of growth hormone (GH) replacement therapy on sympathetic nerve hyperactivity in hypopituitary adults: a double-blind, placebo-controlled, crossover, short-term trial followed by long-term open GH replacement in hypopituitary adults.
by: Sverrisdóttir, Y, et al.
Published: (2003)

Optimal dosage interval for depot somatostatin analogue therapy in acromegaly requires individual titration.
by: Jenkins, P, et al.
Published: (2000)

Growth hormone deficiency and replacement in patients with treated Cushing's Disease, prolactinomas and non-functioning pituitary adenomas: effects on body composition, glucose metabolism, lipid status and bone mineral density.
by: Colson, A, et al.
Published: (2006)

The modulation of platelet function by growth hormone in growth hormone deficient Hypopituitary patients
by: Irene K Oglesby, et al.
Published: (2023-09-01)

The growth hormone secretagogue hexarelin stimulates the hypothalamo-pituitary-adrenal axis via arginine vasopressin.
by: Korbonits, M, et al.
Published: (1999)

Hexarelin as a test of pituitary reserve in patients with pituitary disease.
by: Korbonits, M, et al.
Published: (1999)

Pyridostigmine partially reverses dexamethasone-induced inhibition of the growth hormone response to growth hormone-releasing hormone.
by: Trainer, P, et al.
Published: (1992)

Authors' response: The value of the low-dose dexamethasone suppression test in the differential diagnosis of hyperandrogenism in women
by: Kaltsas, G, et al.
Published: (2003)

The prevalence and characteristic features of cyclicity and variability in Cushing's disease.
by: Alexandraki, K, et al.
Published: (2009)

How common are polycystic ovaries and the polycystic ovarian syndrome in women with Cushing's syndrome?
by: Kaltsas, G, et al.
Published: (2000)

Classic cardiovascular risk factors improve in very elderly hypopituitary patients treated on standard hormone replacement in long term follow- up
by: Isabella Naves Rosa, et al.
Published: (2021-03-01)

CT appearance of the adrenal glands in adrenocorticotrophic hormone-dependent Cushing's syndrome.
by: Sohaib, SA, et al.
Published: (1999)

Complications of inferior petrosel sinus sampling.
by: Kaltsas, G, et al.
Published: (2000)

Circulating Levels of Irisin in Hypopituitary and Normal Subjects.
by: Lara Pena-Bello, et al.
Published: (2016-01-01)

Benzodiazepines attenuate the pituitary-adrenal responses to corticotrophin-releasing hormone in healthy volunteers, but not in patients with Cushing's syndrome.
by: Korbonits, M, et al.
Published: (1995)

Prevalence and risk factors of the metabolic syndrome in young adults with childhood-onset hypopituitary growth hormone deficiency
by: Han Hyuk Lim, et al.
Published: (2010-10-01)

Gamma knife radiosurgery: a safe and effective salvage treatment for pituitary tumours not controlled despite conventional radiotherapy.
by: Swords, F, et al.
Published: (2009)

The role of cytotoxic chemotherapy in the management of aggressive and malignant pituitary tumors.
by: Kaltsas, G, et al.
Published: (1998)

Discriminatory value of the low-dose dexamethasone suppression test in establishing the diagnosis and differential diagnosis of Cushing's syndrome.
by: Isidori, A, et al.
Published: (2003)

Male-female differences in 6-sulfatoxymelatonin excretion in hypopituitary patients
by: Hugo L. Fideleff, et al.
Published: (2016-02-01)

Optimal response criteria for the human CRH test in the differential diagnosis of ACTH-dependent Cushing's syndrome.
by: Newell-Price, J, et al.
Published: (2002)

NITRIC-OXIDE AS A NOVEL REGULATOR OF NEUROENDOCRINE FUNCTION - CONTROL OF CORTICOTROPIN-RELEASING HORMONE-41 RELEASE FROM THE RAT HYPOTHALAMUS INVITRO
by: Costa, A, et al.
Published: (1992)

Expression of the growth hormone secretagogue receptor in pituitary adenomas and other neuroendocrine tumors.
by: Korbonits, M, et al.
Published: (1998)

A rapid method for analyzing serum pro-insulin-like growth factor-II in patients with non-islet cell tumor hypoglycemia.
by: Miraki-Moud, F, et al.
Published: (2005)

A critical analysis of the value of simultaneous inferior petrosal sinus sampling in Cushing's disease and the occult ectopic adrenocorticotropin syndrome.
by: Kaltsas, G, et al.
Published: (1999)

Initial response of young people with thyrotoxicosis to block and replace or dose titration thionamide
by: Claire L Wood, et al.
Published: (2023-01-01)

Clinical, radiological and pathological features of patients with Rathke's cleft cysts: tumors that may recur.
by: Mukherjee, J, et al.
Published: (1997)

BENZODIAZEPINES ATTENUATE THE SERUM CORTISOL RESPONSE TO CORTICOTROPIN-RELEASING HORMONE (CRH) IN HEALTHY-VOLUNTEERS
by: Trainer, P, et al.
Published: (1992)

No clear evidence for an association between GH replacement and relapse of intracranial germ cell tumours: single centre and KIMS experience.
by: Chung, T, et al.
Published: (2010)

Nitric oxide modulates the release of corticotropin-releasing hormone from the rat hypothalamus in vitro.
by: Costa, A, et al.
Published: (1993)